Advertisement

Evidence for adverse effects by G-CSF in some acute lymphoblastic leukemias

  • Author Footnotes
    1 Department of Pathology and Clinical Laboratories, University of Michigan, Fellow Suite 35–1463-16, 2800 Plymouth Road, Building 35, Ann Arbor, MI USA 48109–2800
    Justin Kelley
    Footnotes
    1 Department of Pathology and Clinical Laboratories, University of Michigan, Fellow Suite 35–1463-16, 2800 Plymouth Road, Building 35, Ann Arbor, MI USA 48109–2800
    Affiliations
    Department of Pathology, Michigan Medicine-University of Michigan, Ann Arbor, MI, USA
    Search for articles by this author
  • Laura Cooling
    Correspondence
    Correspondence to: University of Michigan Hospitals, 2F222-UH Blood Bank, 1500 East Medical Center Drive, Ann Arbor, MI USA.
    Affiliations
    Department of Pathology, Michigan Medicine-University of Michigan, Ann Arbor, MI, USA
    Search for articles by this author
  • Author Footnotes
    1 Department of Pathology and Clinical Laboratories, University of Michigan, Fellow Suite 35–1463-16, 2800 Plymouth Road, Building 35, Ann Arbor, MI USA 48109–2800
Published:December 19, 2022DOI:https://doi.org/10.1016/j.transci.2022.103637
      We read with interest the recent article by Tekgunduz and colleagues ‶The effect of granulocyte colony-stimulating factors on survival parameters in pediatric patients with acute lymphoblastic leukemia: a retrospective study″ [
      • Tekgunduz S.A.
      • Aycicek A.
      • Bayram C.
      • Uysalol E.P.
      • Akici F.
      • Ozdemir G.N.
      The effect of granulocyte-colony-stimulating factors on survival parameters in pediatric patients with acute lymphoblastic leukemia: a retrospective study.
      ]. Although therapeutic granulocyte-colony stimulating factor (G-CSF) is effective in reducing neutropenia and infection risks following chemotherapy, prophylactic G-CSF use can increase the risk of treatment-related myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). A link between G-CSF and AML is well established in patients with congenital neutropenia, who require long-term G-CSF support [
      • Vandenberghe P.
      • Beel K.
      Severe congenital neutropenia, a genetically heterogenous disease group with an increased risk of AML/MDS.
      ]. More recent studies have demonstrated a small measurable risk of AML and MDS due to limited prophylactic G-CSF exposure in non-Hodgkin lymphoma and breast cancer patients [
      • Calip G.S.
      • Moran K.M.
      • Sweiss K.I.
      • Patel P.R.
      • Wu Z.
      • Adimadhyam S.
      • et al.
      Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma.
      ,
      • Calip G.S.
      • Malmgren J.A.
      • Lee W.-J.
      • Schwartz S.M.
      • Kaplan H.G.
      Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer.
      ]. More importantly, prophylactic G-CSF in pediatric AML patients is an established risk factor for relapse and is no longer considered standard of care [
      • Lohmann D.J.A.
      • Asdahl P.H.
      • Abrahamsson J.
      • Ha S.-Y.
      • Jonsson O.G.
      • Daspers G.J.L.
      • et al.
      Use of granulocyte colony-stimulating factor and risk of relapse in pediatric patients treated for acute myeloid leukemia according to NOPHO-AML 2004 and DB AML-01.
      ,
      • Creutzig U.
      • van den Heuvel-Eibrink M.M.
      • Gibson B.
      • Dworzak M.N.
      • Adachi S.
      • de Bont E.
      • et al.
      Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel.
      ].

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Transfusion and Apheresis Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Tekgunduz S.A.
        • Aycicek A.
        • Bayram C.
        • Uysalol E.P.
        • Akici F.
        • Ozdemir G.N.
        The effect of granulocyte-colony-stimulating factors on survival parameters in pediatric patients with acute lymphoblastic leukemia: a retrospective study.
        Transf Aph Sci. 2022; 61103366https://doi.org/10.1016/j.transci.2022.103366
        • Vandenberghe P.
        • Beel K.
        Severe congenital neutropenia, a genetically heterogenous disease group with an increased risk of AML/MDS.
        Pediatr Rep. 2011; 3https://doi.org/10.4081/pr.2011.s2.e9
        • Calip G.S.
        • Moran K.M.
        • Sweiss K.I.
        • Patel P.R.
        • Wu Z.
        • Adimadhyam S.
        • et al.
        Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma.
        Cancer. 2019; 125: 1143-1154https://doi.org/10.1002/cncr.31914
        • Calip G.S.
        • Malmgren J.A.
        • Lee W.-J.
        • Schwartz S.M.
        • Kaplan H.G.
        Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer.
        Breast Cancer Res Treat. 2015; 154: 133-143https://doi.org/10.1007/s10549-015-3590-1
        • Lohmann D.J.A.
        • Asdahl P.H.
        • Abrahamsson J.
        • Ha S.-Y.
        • Jonsson O.G.
        • Daspers G.J.L.
        • et al.
        Use of granulocyte colony-stimulating factor and risk of relapse in pediatric patients treated for acute myeloid leukemia according to NOPHO-AML 2004 and DB AML-01.
        Pedia Blood Cancer. 2019; 66e27701https://doi.org/10.1002/pgc.27701
        • Creutzig U.
        • van den Heuvel-Eibrink M.M.
        • Gibson B.
        • Dworzak M.N.
        • Adachi S.
        • de Bont E.
        • et al.
        Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel.
        Blood. 2012; 120: 3187-3205https://doi.org/10.1182/blood-2012-03-362608
        • Ode D.L.
        • Zhou M.
        • Findley H.W.
        • Ragab A.H.
        The effect of recombinant GM-CSF and B-CSF on the bone marrow cells of children with acute lymphoblastic lymphoma.
        Leukemia. 1992; 6: 1210-1212
        • Tan M.
        • Chen M.-L.
        • Chen Y.-Z.
        • Wu Y.
        Expression and role of granulocyte macrophage colony-stimulating factor receptor (GM-CSFR) and granulocyte colony-stimulating factor receptor (G-CSFR) on Ph-positive acute B lymphoblastic leukemia.
        Hematol. 2018; 23: 439-447https://doi.org/10.1080/10245332.2018.146540
        • Nishihara M.
        • Wada Y.
        • Ogami K.
        • et al.
        A combination of stem cell factor and granulocyte colony-stimulating factor enhances the growth of human progenitor B cells supported by murine stromal cell line MS-5.
        Eur J Immunol. 1998; 28: 855-864https://doi.org/10.1002/(SICI)1521-4141(199803)28:03,855::AID-IMMU855>3.0.co;2-x
        • Inukai T.
        • Sugita K.
        • Iijima K.
        • Goi K.
        • Tezuka T.
        • Kojika S.
        • et al.
        Leukemic cells with 11q23 translocations express granulocyte colony-stimulating factor (G-CSF) receptor and their proliferation is stimulated with G-CSF.
        Leukemia. 1998; 12: 382-389https://doi.org/10.1038/sj.leu.2400951
        • Handa A.
        • Kashimura T.
        • Takeuchi S.
        • Yamamoto A.
        • Murohashi I.
        • Bessho M.
        • Hirashima K.
        Expression of functional granulocyte colony-stimulating factor receptors on human B-lymphoblastic leukemia cells.
        Ann Hematol. 2000; 79: 127-131https://doi.org/10.1007/s002770050567
        • Tsuchiya H.
        • El-Sonbaty S.S.
        • Watanabe M.
        • Suzushima H.
        • Asou N.
        • Murakami T.
        • et al.
        Analysis of myeloid characteristics in acute lymphoblastic leukemia.
        Leuk Res. 1993; 17: 809-813https://doi.org/10.1016/0145-2126(93)90116-3
        • Stanulla M.
        • Kasper B.
        • Schrappe M.
        • et al.
        Granulocyte colony-stimulating factor receptor expression and 11q23/MLL genotype in childhood acute lymphoblastic leukemia developing during the first 18 months of life.
        Leukemia. 2000; 14: 337-338https://doi.org/10.1038/sj.leu.2401653
      1. Basnett J., Xie V., Cisterne A., Bradstock K., Bendall L. Regulation of the bone marrow microenvironment by G-CSF: Effects of G-CSF on acute lymphoblastic leukaemia. PLoS One 12:e0188042. https://doi.org/10.1371/journal.pone.0188042.

        • Schroeder M.A.
        • DiPersio J.F.
        Mobilization of hematopoietic stem and leukemia cells.
        J Leukoc Biol. 2012; 91: 47-57https://doi.org/10.1189/jlb.0210085
        • Kobbe G.
        • Bauser U.
        • Rieth C.
        • Hunerliturkoglu A.
        • Sohngen D.
        • Aivado M.
        • Heyll A.
        Granulocyte colony-stimulating factor (G-CSF) mediated mobilization of leukemic cells in Philadelphia chromosome positive acute lymphoblastic leukemia expressing myeloid antigen (my+Ph+ALL).
        Am J Hematol. 1998; 58: 330-333https://doi.org/10.1002/(sici)1096-8652(199808)58:4<330::aid-ajh14>3.0.co;2-b
        • Hoffmann S.
        • Cooling L.
        • Sexton E.
        • et al.
        Stem cell mobilization uncovering a de novo acute lymphoblastic leukemia [abstract].
        J Clin Apher. 2021; 36: 28-29